Dr KSS wrote about SCYX last month. He explained how they have an anti-fungal drug underway that would be very helpful as an adjunct to the many anti-bacterial drugs already on the market. An anti-fungal would be a bit unique and therefore valuable, he explained. However, I just read that SCYX sold their product (all their cyclophilin inhibitor assets). Does this mean they just sold out of their rights to the anti-fungal material Dr. KSS was discussing?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
I’m no medical expert but it seems that SCYX only sold non-core assets, not the ones that Dr KSS wrote about.
See: https://globenewswire.com/news-release/2016/07/13/855696/0/en/SCYNEXIS-Inc-Announces-Sale-of-Cyclophilin-Inhibitor-Assets-to-Cypralis-Limited.html
All the best MK
I would really LOVE an update on what has been/is going on with SCYX.
I see that it is up 28% today — and I could exit with a nice profit.
However, if Dr. KSS thinks it’s still the potentially potent long term play he originally did, I’m more than willing to be patient.
I may just not be searching efficiently, but I can’t seem to find ANY recent substantive posts about this stock– have I quite literally “lost the thread”?
SCYX long – Tony, articles by author KSS most recent alway on top. 🙂 http://www.stockgumshoe.com/author/dr-kss-md-phd/ Best2You-Ben